Adamis Pharmaceuticals Corporation (ADMP) stock surged in the extended-hours session last night as the specialty pharmaceutical giant’s share price rose 90.5% to $2.42.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
A specialty biopharmaceutical company, Adamis Pharmaceuticals Corporation (ADMP), focuses on developing and commercializing products for various clinical indications, including allergy, opioid overdose, respiratory disease, and inflammatory disease. The FDA has approved the SYMJEPI (epinephrine) Injection products to treat a variety of acute allergic reactions, including anaphylaxis.
- Top 3 Cloud Computing Stocks to Watch For in 2021
- 3 Best Work-From-Home Stocks for Long-term Investment
What happened there…
Adamis Pharmaceuticals Company (NASDAQ: ADMP) has announced that its Sympine Pulse Injectors are now available for $99.99, the lowest price advertised by the Walgreens Prescription Savings Club for epinephrine drugs and the lowest price available on the market for epinephrine devices1 to members of the Walgreens Prescription Saving Club.
The Walgreens Drug Discount Club scheme included Adamis’ SYMJEPI 0.3mg and SYMJEPI 0.15mg Injection drugs used in the emergency management of acute allergic reactions at the beginning of 2021. The Walgreens Drug Discount Club provides substantial savings from retail rates on thousands of drugs to shoppers who pay an annual subscription fee.
Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, added, “We’re delighted Walgreens has introduced SYMJEPI to their drug discount club, and we hope this service will make good use of this possibly life-saving treatment for the patients who most need it. Adamis continues to make SYMJEPI the most affordable product for patients.”
Experts are of the opinion that we are living in the prime time of the pharmaceutical industry. Science is providing new insights into the prevention and treatment of diseases previously unknown. The pharmaceutical industry is likely to offer investors huge returns during this period if they can attain approval from authorities.